Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA5221-T (SGLT-2 inhibitor) added to DA5221-B1 and DA5221-B2 (DPP-4 inhibitor) in type 2 diabetes
NCT06290349Phase 3Active, not recruiting
- Sponsor
- Dong-A ST
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of DA-5221 in type 2 diabetes mellitus (T2DM), sponsored by Dong-A ST. Started Apr 2024; status: active, not recruiting.
02
Drugs
DA-5221
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06290349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290349.